Pharmaceuticals · NYSE

BMYBristol Myers Squibb Co

Last close
$63.43 +1.8%
52-week range
$45.27 to $68.64
Market cap
$130B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$48.2B
-0% vs FY24
Net income
$7.05B
+179% vs FY24
Free cash flow
$12.8B
-8% vs FY24
Net cash
-$36.4B
Cash $10.7B, debt $47.1B

Stock price

+11% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on 3 of 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
14.1x
12.0x241x
13th percentile, below its median of 20.1x
Positive-earnings quarters only
Price / sales
2.6x
1.8x5.1x
28th percentile, below its median of 3.3x
EV / EBITDA
10.2x
7.0x49.0x
35th percentile, below its median of 12.3x
Price / free cash flow
14.0x
6.0x53.3x
78th percentile, above its median of 11.1x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
14.1x
Earnings yield
7.1%
Price / sales
2.6x
Price / book
5.5x
Price / operating cash flow
12.2x
EV / EBITDA
10.2x
EV / sales
3.2x
Free cash flow yield
7.2%

Profitability

Gross margin
69.2%
Operating margin
n/a
Net margin
18.5%
Return on equity
39.5%
Return on capital
n/a

n/a: Not reported

Growth per year

Revenue, 3 years
+1.4%
Revenue, 5 years
+2.5%
Revenue, 9 years
+10.6%
EPS, 3 years
+5.5%

Balance sheet

Cash and investments
$12.6B
Total debt
$43.6B
Net cash
-$31.1B
Debt / equity
1.86x
Current ratio
1.59x

Shares and dividend

Shares outstanding
2.04B
Share count, 5 years
-9.7%
Beta, 1 year
0.23
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
55.4%

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $13.1B
RevenueNet income
Gross profitLatest quarter $8.92B
EBITDALatest quarter $3.56B
Margins68 / 17%
GrossOperatingNet
Earnings per shareLatest quarter $1.05
Cash flowLatest quarter $4.18B
OperatingCapexFree
Cash vs debtLatest quarter $12.6B
Cash and investmentsTotal debt
P/E historyNow 14.1x
P/E, median 20.1x dashed
P/S historyNow 2.6x
P/S, median 3.3x dashed

Where the revenue comes from

Revlimid went from 22% to 6% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

Legacy BrandsOpdivoOrenciaRevlimidYervoyPomalyst ImnovidOther
FY22
18%22%
$46.2B
FY23
20%8%14%
$45.0B
FY24
19%12%
$48.3B
FY25
45%21%9%
$48.2B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Legacy Brands$21.8B45.2%n/a
Opdivo$10.0B20.9%+8%
Orencia$3.71B7.7%+1%
Revlimid$2.95B6.1%-49%
Yervoy$2.90B6.0%n/a
Pomalyst Imnovid$2.73B5.7%-23%
Other$4.25B8.8%+24%

Pharmaceuticals peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
LLY ELI LILLY & Co $1.36T +46% n/a46.8x15.7x 60th percentile
JNJ Johnson & Johnson $688B +8% n/a43.4x6.9x 90th percentile
MRK Merck & Co., Inc. $364B +5% n/a152x5.4x 98th percentile
PFE Pfizer Inc $165B +1% n/a41.2x2.6x 97th percentile
BMY Bristol Myers Squibb Co $130B +4% n/a14.1x2.6x 13th percentile
TEVA Teva Pharmaceutical Industries Ltd $51.9B -16% 10.2%103x3.7x Not enough history

The company

Sector
Health Care
Industry
Pharmaceuticals
CEO
Giovanni Caforio
Employees
30,000 (as of 2019)
Founded
1989
Headquarters
Princeton, NJ
Fiscal year ends
December
Website
bms.com

What it does

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about BMY.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 2,201 active funds. Crowd level: quiet.

Open the Smart money tab